Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Randomized Controlled Trial Shows Circumcision Does Not Reduce Male-To-Female HIV Transmission
- Pharmacists' Association Executive To Receive The Food And Drug Administration's Commissioner's Special Citation Award
- APhA Publishes New Print, CD-ROM Editions Of Handbook Of Pharmaceutical Excipients
- Society Marks 100th Day Of Its Commitment To The Profession - Royal Pharmaceutical Society of Great Britain
- Oncolytics Biotech(R) Inc. Announces Start Of Enrolment In U.S. Phase 2 Melanoma Cancer Clinical Trial
- Texas State Lawmaker Requests Information On Licenses For Dispensing Mifepristone
- Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance For Proposed INTERCEPT Blood System Phase III Trial Design
- Noven Reports Positive Phase 2 Results For Mesafem™ Non-Hormonal Therapy For Vasomotor Symptoms
- Couples To Rely On Male Contraceptive For New Trial, UK
- FDA Okays Certolizumab Pegol for Rheumatoid Arthritis
Stellar Pharmaceuticals Inc. Announces Watson Pharma, Inc. Has Received A Conditional IDE Approval For Stellar’s Uracyst(R) From The FDA
Posted by: admin in Pharmacy Drugs on June 12th, 2009
Stellar Pharmaceuticals Inc. (”Stellar” or the “Company”) (OTCBB:SLXCF) is pleased to announce that its United States licensee, Watson Pharma, Inc. (”Watson”) (NYSE:WPI), has received a conditional approval of their Investigational Device Exemption (IDE) to conduct clinical work with Uracyst® from The fda.gov/” rel=”nofollow”>Food and Drug Administration (FDA) in the United States of America (”USA”). This will allow Watson to continue to move their Uracyst® development program forward towards the eventual approval for the sale of Uracyst® in USA. The conditional approval allows Watson to begin a blinded, placebo-controlled, pilot clinical trial in 100 subjects at 20 clinical study centers in the USA.
Peter Riehl, Stellar’s President and CEO stated, “We are very pleased to see another important milestone completed by Watson as they continue to make progress towards the sale of Uracyst® in the largest pharmaceutical market in the world. Stellar is fortunate to have a partner as experienced as Watson is in the field of urology to develop the clinical program for the Uracyst marketing approval in the USA.”
Source
Stellar
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.